1 / 57

Survivor Products: Managing longevity risk & mortality improvements

Survivor Products: Managing longevity risk & mortality improvements. Professor David Blake Director Pensions Institute Cass Business School d.blake@city.ac.uk. The problem. Nothing is certain in life except death and taxes (B Franklin).

MartaAdara
Télécharger la présentation

Survivor Products: Managing longevity risk & mortality improvements

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Survivor Products: Managing longevity risk & mortality improvements Professor David Blake Director Pensions Institute Cass Business School d.blake@city.ac.uk

  2. The problem • Nothing is certain in life except death and taxes (B Franklin). • Over last 20 years, it has become clear that, while death is no less inevitable than before: • it is getting later • and its timing has become increasingly uncertain.

  3. The problem • When British welfare state began in 1948, men could draw their state pension at 65 and expect to live until 67 and only a few lived beyond 70. • At beginning of 21st Century, British men can still draw their pension from age 65 but now live into their early 80s. • Significant proportion of women living into their late 80s.

  4. Mortality improvements over time

  5. Mortality improvements over time

  6. What is longevity risk?(Broken limits to life expectancy – Oeppen & Vaupel)

  7. Stochastic nature of mortality improvements • Evident for many years that mortality rates have been evolving in apparently stochastic fashion. • Sequences do exhibit general trend, but changes have an unpredictable element: • not only from one period to next • but also over the long run.

  8. Longevity risk • Large number of products in life insurance and pensions have mortality as key source of risk. • Products exposed to unanticipated changes over time in mortality rates of relevant reference populations. • Eg annuity providers exposed to risk that mortality rates of pensioners will fall at faster rate than accounted for in pricing and reserving calculations: • Current pool of annuitants living 2 years longer than anticipated

  9. Longevity risk • Annuities are commoditised products selling on basis of price, profit margins have to be kept low in order to gain market share. • If mortality assumption built into price of annuities turn out to be gross overestimate, cuts straight into profit margins of annuity providers. • Most life companies claim to lose money on annuity business.

  10. Longevity risk • Yet life annuities are mainstay of pension plans throughout the world: • they are the only instrument ever devised capable of hedging longevity risk. • Without them, pension plans will be unable to perform their fundamental task of protecting retirees from outliving their resources for however long they live. • Real danger that they might disappear from financial scene.

  11. Longevity risk • Equitable Life: • Embedded options in annuity contracts became very valuable in 1990's due to combination of falling interest rates and improvements in mortality. • Problems avoided if EL could hedge exposures to: • interest-rate risk • mortality improvement risk.

  12. Longevity risk in UK pension provision, £billion of total liabilities- broad estimates: end 2003 Figure 5.17 p181

  13. Significant concern! Reinsurers (eg Swiss Re) have stopped reinsuring longevity risk of life offices!

  14. Survivor Products • Long-dated survivor bonds: • Life annuity bond: coupon payments decline in line with mortality index: • Eg based on population of 65-year olds on issue date. • As population cohort dies out, coupon payments decline, but continue in payment until the entire cohort dies. • Eg, if after one year 1.5% of population has died out, 2nd year’s coupon payment is 98.5% of 1st year’s etc

  15. Survivor Products • Bond holder, eg life office writing annuities, protected from aggregate mortality risk it faces. • Based on Tontine Bonds issued by European governments in 17th and 18th centuries • Recently revived by Blake and Burrows (2001) and Lin and Cox (2004).

  16. BNP Paribas Longevity Bond • November 2004 • Issuer: European Investment Bank (AAA) • Issue: £540m, 25 year • Mortality index: 65 year-old males from England & Wales (ONS) • Structurer/manager: BNP Paribas (assumes longevity risk) • Reinsurer of lengevity risk: PartnerRe, Bermuda • Investors: UK pension funds

  17. BNP Paribas Longevity Bond

  18. Advantages of longevity bond • Provides better match for liabilities of pension funds and life insurers than other available investments: • other than purchasing (re)insurance to cover the longevity risk (i.e annuities) • Bond also provides long term interest rate hedge. • Longevity index transparent • EIB has AAA credit rating. • Life insurers holding longevity bond as hedge may be able to hold lower prudential margins.

  19. Survivor Products • Short-dated, mortality-linked securities: • Market-traded securities whose payments are linked to mortality index • Similar to catastrophe bonds (Schmock, 1999, Lane, 2000, Wang, 2002, and Muermann, 2004)

  20. Swiss Re Bond 2003 • Designed to securitise Swiss Re’s own holding of mortality risk! • 3-year contract (matures 1 Jan 2007) which allows issuer to reduce exposure to catastrophic mortality events: • severe outbreak of influenza • major terrorist attack (WMD) • natural catastrophe. • Mortality index (MI): • US (70%), UK (15%), France (7.5%), Italy (5%), Switzerland (2.5%). • Male (65%), Female (35%) • Also age bands

  21. Influenza pandemics • All resulted from avian flu virus mutating with human flu virus • 11 outbreaks in 300 years • 1580 • First confirmed flu pandemic • 1782 • Summer Flu • Started in China • Hit young adults • 1889 • Russian Flu • Over 20% of world population infected • 1m deaths

  22. Influenza pandemics • 1918-19 • Spanish Flu • Started in Kansas • Killed 50m people worldwide: • 250,000 in UK • More than died in WW1, in shorter period • 20% of world’s population infected and 1% killed • Spread along trade routes and shipping lines

  23. Influenza pandemics • 1957-58 • Asian Flu • 2m deaths • Hit teenagers hardest • Spread around world in 6 months • 1968-69 • Hong Kong Flu • Started in China • 1m deaths • Spread slowly with moderate symptons

  24. Influenza pandemics • 2005-06 • Started in SE Asia • H5N1 virus • Closely related to 1918 Spanish virus

  25. Swiss Re Bond 2003 • $400m, principal at risk ‘if, during any single calendar year, combined mortality index exceeds 130% of baseline 2002 level’. • Principal exhausted if index exceeds 150% • Equivalent to a call option spread on the index with: • Lower strike price of 130% • Upper strike price of 150% • Investors get quarterly coupons of 3-mo USD Libor + 135bp

  26. Swiss Re Bond 2003

  27. Swiss Re Bond 2003

  28. Swiss Re Bond 2003 • Bond valued using Extreme Value Theory (Beelders & Colarossi (2004)) • Assume Generalised Pareto Distribution • Probability of attachment: • P[MI(t)>1.3MI(2002)] = 0.33% • Probability of exhaustion: • P[MI(t)>1.5MI(2002)] = 0.15% • Expected loss = 22bp < 135bp • A good deal for investors! • Bond trading at Libor + 100bp in June 2004

  29. Survivor Products • Survivor swaps: • Counterparties swap fixed series of payments in return for series of payments linked to number of survivors in given cohort: • UK annuity provider could swap cash flows based on UK mortality index for cash flows based on US mortality index from a US annuity provider counterparty • Would enable both counterparties to diversify their longevity risks internationally. • Dowd et al (2004)

  30. Survivor Products • Annuity futures: • Prices linked to specified future market annuity rate • Mortality options: • Payout depends on underlying mortality table at payment date. • Eg, EL guaranteed annuity contract

  31. Demand side of market • Reference population underlying calculation of mortality rates central to both: • Viability • Liquidity of contracts. • Hedging demand from investors (eg life offices) wishing to hedge mortality exposures. • If reference population v different from investor’s specific population, then investor will be exposed to significant basis risk: • Might conclude that mortality derivative is not worth holding.

  32. Demand side of market • Speculative demand: • depends on liquidity. • Adequate liquidity will require small number of reference populations: • Need to be chosen carefully to ensure that level of basis risk is small for investors with hedging demands. • Demand from hedge funds: • seeking instruments that have low correlation with existing financial instruments

  33. Supply side of market • Government: • Securitising social security budget • Corporates long longevity risk: • Pharamceuticals

  34. Barriers to development in cash market • After more than year, BNP Paribas longevity bond had not generated sufficient demand to be launched: • Has been withdrawn for redesign • Suggests significant barriers need to be overcome before sustainable market in survivor products and derivatives emerges.

  35. Barriers to development in cash market • Reasons why BNP bond did not launch: • design issues • which make bond an imperfect hedge for longevity risk • pricing issues • institutional issues

  36. Design issues • Small scheme will find it difficult to use bond to match its liabilities: • as variance between actual and expected mortality will be quite large. • Mortality experience of individual pension funds and life insurers may be different from reference UK population. • Bond only provides hedge for longevity of males: • pension funds and life insurers also exposed to significant longevity risk from females.

  37. Design issues • Liabilities for pension funds and life insurers give greater weight to the lives receiving larger pensions. • Further, significant differences in mortality of those receiving larger pensions compared to those receiving lower pensions. • As payments under bond effectively give equal weight to all the lives in the UK population, the already imperfect hedge provided by the longevity bond is worsened.

  38. Design issues • Bond only matches cashflow under level pension • while large portion of pensions paid by pension funds and life insurers will be increasing at RPI/LPI. • Bond is progressively worse hedge for pension liabilities related to younger or older cohorts.

  39. Pricing issues • Need to forecast mortality index MI’s • Need to estimate r’s • Correlation between MI and r: • Anticipated to be low

  40. Pricing issues • Above model valid only in complete market • In incomplete market, need to convert projected deterministic mortality rates into risk-neutral probabilities • E.g using Wang transform • Lin & Cox (2005)

  41. Pricing issues • Longevity risk premium built into initial price of bond set at 20 basis points. • Given that this is first ever bond brought to market, markets have no real feeling as to how fair this figure is. • However, concern that up-front capital was too large compared with risks being hedged by bond: • longevity and interest rate risks • leaving no capital for other risks to be hedged • e.g. inflation

  42. Institutional issues • Issue size too small to create liquid market. • Consultants reluctant to recommend it to trustees. • Fund managers do not currently have mandate to manage longevity risk. • Fund managers have not welcomed bond: • since believe it would be closely held and they would not make money from it being traded. • Partner Re is unlikely to be perceived as being a natural holder of UK longevity risk.

  43. Institutional issues • Last point highly significant • Reflects view that key determinant of future issue of longevity bonds is availability of sufficient reinsurance capacity. • Neither UK-based nor EU-based reinsurer willing to provide cover for BNP bond • Partner Re not prepared to offer cover above issue size of £540m. • Has been questioned whether EU’s solvency requirements render reinsurance cover within EU prohibitively expensive.

  44. Barriers to development in futures market • Following factors key to success of particular futures contract: • defined as having consistently high volume of trade and open interest: • Must be large, active and liquid spot market for underlying with good price transparency: • by far the most important factor: • indeed no futures contract has ever survived without a spot market satisfying these conditions.

  45. Barriers to development in futures market • Spot prices must be sufficiently volatile to create hedging needs and speculative interest. • Relative hedging demand can be measured by level of open interest relative to volume: • since former excludes the many speculators who do not hold overnight positions. • Low open interest to volume ratio is an indication of high liquidity : • another sign of successful futures contract.

  46. Barriers to development in futures market • Underlying must be homogeneous and/or have well-defined grading system. • Market in underlying must not be heavily concentrated on either buy or sell side: • since this can lead to price manipulation. • Futures contract must be effective in reducing risk.

  47. Barriers to development in futures market • Liquidity costs: • bid-ask spreads • execution risk: • risk of adverse price movements before trade execution • Liquidity costs in the futures contract must not be significantly higher than those operating in any existing cross-hedge futures contract.

  48. Failure of futures contracts • CPI futures contract listed on US Coffee, Sugar and Cocoa Exchange in June 1985 • Delisted in April 1987 with only 10,000 contracts traded. • Reasons for failure: • no inflation-linked securities market at the time. • underlying was infrequently published index. • no stable pricing relationship with other instruments.

More Related